| Name | Title | Contact Details |
|---|
Better Therapeutics ("Better") is developing first-in-class prescription digital therapeutics to deliver behavioral therapy to patients. Led by an experienced team of biotechnology executives with funding from top-tier industry investors, Better expects to go public through a merger with SPAC Mountain Crest Acquisition Corp. (NASDAQ: MCAD) during the summer of 2021. Better was founded upon the realization that nearly half a trillion dollars are spent each year treating the symptoms or effects of cardiometabolic diseases while little is being done to address the behaviors that cause them. Better has created prescription software that it believes has the opportunity to fundamentally change the treatment of a broad range of cardiometabolic diseases beginning with type 2 diabetes. The team is focused on creating significant patient impact through the launch of their first product in 2023. Better is developing a portfolio of regulated software products that treat the root causes of disease, improving the health and quality of life of patients while giving providers and payers access to cost-effective digital behavior therapies.
Datavant connects healthcare data to eliminate the silos of healthcare information that hold back innovative medical research and improved patient care. We help data owners manage the privacy, security, compliance, and trust required to enable safe data sharing. Datavant`s vision is backed by Roivant Sciences, Softbank, and Founders Fund, and combines technical leadership and healthcare expertise. Datavant is located in the heart of San Francisco`s Financial District.
VGA Billing Services is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
South Pacific Bio Medical is a Temecula, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sherlock Biosciences aims to disrupt molecular diagnostics with better, faster, affordable tests. With our unique Engineering Biology platforms, we are on the cusp of solving challenges ranging from faster pathogen detection and simpler testing for cancer to improved food safety. We envision a world where our products will enable users to make more effective decisions in any environment, whether in hospitals, industrial settings, the developing world, or at home. Our team and founders include Engineering Biology pioneers with world-leading expertise in CRISPR and Synthetic Biology, diagnostic industry veterans, and disease-area authorities. Together, they provide an unparalleled set of capabilities that are transforming molecular diagnostics in clinical and non-clinical settings.